항생제 내성 시장 : 현황 분석 및 예측(2024-2032년)

Antimicrobial resistance is a very sensitive and evolving threat within the healthcare market and is indicated by the emergence of multidrug-resistant organisms, to which standard antibiotics are ineffective. These increased rates have made treatment failures become more common, lengths of stay rise, and costs skyrocket, all of which have created the need for new approaches that will address the issues. Industry is keen on investing in the development of new antibiotics and other therapies, and in diagnostics tools because of the high threat level of resistant infections in patients. Other opportunities are related to the geographical areas of diagnostics advances and international partnerships that call for an active strategy to fight antibiotic resistance. In conclusion, there is great potential within the market as key players are aware that increased awareness for practical solutions to reducing the burden of antibiotic resistance on the population is needed.

The Antibiotic Resistance Market is expected to grow at a steady rate of around 5.4% owing to the rising research & development activities. For instance, in November 2022, the Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched to ensure the growing threats and impacts of antimicrobial resistance are addressed globally. The Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH), known as the Quadripartite are joining forces on this initiative to underscore the threat antimicrobial resistance presents to humans, animals, plants, ecosystems, and livelihoods. Moreover, increasing cases of antibiotic-resistant infections and increasing investment in antibiotic research and development activities boost the antibiotic resistance market.

Based on the disease type, the market is segmented into urinary tract infections, intra-abdominal infections, bloodstream infections, clostridium difficile infections, and others. The urinary tract infections (UTIs) segment held a significant share of the market in the year 2023 owing to increased incidence of UTIs especially among females, elder people, and those with chronic diseases. As the frequency of antibiotic-resistant strains like Escherichia coli rises, traditional treatments are becoming less effective and the market for new antibiotics as well as other forms of therapy is growing rapidly. Since these infections are difficult to manage by most healthcare providers, more focus is being placed on the development of specific treatments, diagnostics, and preventive measures. Furthermore, an increased realization of antibiotic resistance consequences has boosted efforts and funding towards UTI-tailored treatments. This segment is expected to see a lot of activities from the stakeholders as there is a need to come up with effective treatment for the condition and come up with intensified management measures towards combating the increased cases of resistance in antibiotic use; especially in UTIs.

Based on the pathogen type, the market is segmented into Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and others. The Staphylococcus aureus segment is expected to experience significant growth in the forecast period owing to infections by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive strains, which are becoming resistant to other antibiotic classes. S. aureus is a pathogen that is recognized to cause diverse healthcare-associated and community-acquired skin infections, pneumonia, bacteremia, and other infections that urge the need for effective treatment. The new form of resistance requires the drug companies to develop new antibiotics targeting resistant bacteria, and new treatments including monoclonal antibodies and bacteriophage therapies. Thus, the Staphylococcus aureus segment is expected to grow at a significant rate in the forecast period among the pathogen type.

Based on the drug class, the market is segmented into oxazolidinones, lipoglycopeptides, tetracyclines, and others. The oxazolidinones segment is expected to experience significant growth in the forecast period owing to rising instances of multidrug-resistant Gram-positive infections especially, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Among the oxazolidinones, linezolid and tedizolid have become valuable therapeutic agents for managing these hard-to-treat infections owing to the new pathway through which bacterial protein synthesis is blocked. Due to the increased resistance to conventional antibiotics, the global market for new-generation antibiotics such as oxazolidinones is being introduced. In addition, the increased number of applications of these agents in clinical settings together with continuous efforts into the development of new oxazolidinone compounds also put thrust on this market. The oxazolidinones market has the potential to ensure that users get effective treatments for resistant infections and it thus plays an essential role in treating antibiotic resistance and maximizing patient health in healthcare organizations. Thus, the oxazolidinones segment is expected to grow at a significant rate in the forecast period among the drug class.

For a better understanding of the market adoption of antibiotic resistance, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the majority share of the market in the year 2023. The trends influencing the antibiotic resistance market growth in North America are the growing rate of the market and the recognition of antibiotic resistance as a significant threat among healthcare providers and the overall population. The strong health system of the region enables the development of innovative antibiotics and other technologies and diagnostic tools that strive to address and identify resistant strains in the early stages. Further, the launch of the National Action Plan for Combating Antibiotic-Resistant Bacteria by the U.S government increased funding between public health entities, pharmaceuticals, and academic institutions. Healthcare facility-high antibiotic stewardship programs also contribute towards increasing efforts to find ways to counter resistance. For instance, Entasis, a pioneer in the development of novel, anti-infective therapies, and La Jolla Pharmaceutical Company (La Jolla), with proven capabilities in commercializing medicines in critical care and hospital settings. Innoviva completed the acquisitions of Entasis and La Jolla in 2022. Thus, amongst areas, North America held a significant share of the market in the year 2023.

Some of the major players operating in the market include Pfizer Inc.; Orchid Chemicals & Pharmaceuticals Limited; Melinta Therapeutics, LLC; Innoviva Specialty Therapeutics; Basilea Pharmaceutica Ltd; Wockhardt Limited; Paratek Pharmaceuticals, Inc.; Seres Therapeutics, Inc.; Cipla; Merck & Co. Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Antibiotic Resistance Market
• 2.2. Research Methodology of the Antibiotic Resistance Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL ANTIBIOTIC RESISTANCE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DISEASE TYPE

• 7.1. Urinary Tract Infection
• 7.2. Intra-Abdominal Infections
• 7.3. Blood Stream Infections
• 7.4. Clostridium Difficile Infections
• 7.5. Others

8.MARKET INSIGHTS BY PATHOGEN TYPE

• 8.1. Acinetobacter Baumannii
• 8.2. Pseudomonas Aeruginosa
• 8.3. Staphylococcus Aureus
• 8.4. Streptococcus Pneumoniae
• 8.5. Others

9.MARKET INSIGHTS BY DRUG CLASS

• 9.1. Oxazolidinones
• 9.2. Lipoglycopeptides
• 9.3. Tetracyclines
• 9.4. Others

10.MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

• 11.1. List of Market Participants

12.COMPETITIVE LANDSCAPE

• 12.1. Competition Dashboard
• 12.2. Competitor Market Positioning Analysis
• 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

• 13.1. Pfizer Inc.
  • 13.1.1. Company Overview
  • 13.1.2. Key Financials
  • 13.1.3. SWOT Analysis
  • 13.1.4. Product Portfolio
  • 13.1.5. Recent Developments
• 13.2. Orchid Chemicals & Pharmaceuticals Limited
• 13.3. Melinta Therapeutics, LLC
• 13.4. Innoviva Specialty Therapeutics
• 13.5. Basilea Pharmaceutica Ltd
• 13.6. Wockhardt Limited
• 13.7. Paratek Pharmaceuticals, Inc.
• 13.8. Seres Therapeutics, Inc.
• 13.9. Cipla
• 13.10. Merck & Co. Inc.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE